8-K: Propanc Biopharma Secures $33,000 Convertible Note to Bolster Working Capital

Propanc Biopharma has entered into a securities purchase agreement for a $33,000 convertible note to fund general working capital.

Summary

• Propanc Biopharma has secured a $33,000 convertible note from GS Capital Partners, LLC, with a purchase price of $30,000 due to an original issue discount.
• The note bears an 8% annual interest rate, payable in common stock, and matures on March 20, 2025.
• The note is convertible into common stock at a fixed price of $0.0003 per share, which can decrease to $0.0001 per share if the stock trades below $0.0003 for more than five consecutive days.
• In the event of default, the conversion price will be the lowest trading price of the common stock in the ten days prior to the default, adjusted every 30 days if the default continues.
• The note can be prepaid with premiums ranging from 110% to 125% of the principal plus accrued interest, depending on the prepayment date within the first 180 days.
• A change of control event triggers a 150% redemption of the principal plus accrued interest, or the holder can convert the note into common stock prior to the event.
• The company has reserved 450,000,000 shares of common stock for conversions under this note.

Sentiment

Score: 4

Explanation: The document indicates a necessary but potentially risky financing event. While the company secures needed capital, the terms of the note, including the high default interest rate and potential for dilution, are concerning.

Positives

• The convertible note provides Propanc Biopharma with $30,000 in immediate funding for working capital.
• The conversion feature allows the investor to participate in potential upside of the company's stock.
• The prepayment option provides flexibility for the company to manage its debt.
• The company has reserved a significant number of shares for potential conversion, indicating a commitment to fulfilling its obligations.

Negatives

• The note includes a significant original issue discount, reducing the net proceeds to the company.
• The conversion price can be adjusted downwards if the stock price declines, potentially increasing dilution.
• The default interest rate of 24% is very high, creating a significant risk for the company.
• The note contains numerous events of default that could trigger immediate repayment.
• The company is required to pay all transfer agent costs and legal fees associated with issuing and delivering the shares to the Holder.

Risks

• The company faces the risk of default if it fails to meet its obligations under the note, including payment of principal and interest.
• The conversion of the note could significantly dilute existing shareholders.
• The company's stock price could fall below the conversion price, potentially triggering a lower conversion price and further dilution.
• The company's ability to prepay the note is limited to the first 180 days and comes with significant premiums.
• The company is subject to numerous events of default, including failure to maintain its stock listing or comply with SEC reporting requirements.

Future Outlook

The company intends to use the net proceeds from the note for general working capital purposes.

Management Comments

• The company has not provided any direct quotes in this document.

Industry Context

This type of financing is common for small, publicly traded companies seeking to raise capital, particularly those in the biotechnology sector. Convertible notes are often used as a bridge to future equity financing.

Comparison to Industry Standards

• The terms of this convertible note, including the interest rate, conversion price, and prepayment premiums, are relatively standard for small-cap companies.
• The conversion price of $0.0003 per share, with a potential decrease to $0.0001, is typical for companies with low stock prices.
• The default interest rate of 24% is high, reflecting the risk associated with investing in a company with a low market capitalization.
• The prepayment premiums are also standard for this type of financing, designed to compensate the investor for early repayment.

Stakeholder Impact

• Shareholders face potential dilution from the conversion of the note.
• Creditors are impacted by the terms of the note, including the default provisions.
• Employees may be affected by the company's financial stability and ability to operate.

Next Steps

• The company will use the funds for general working capital.
• The company will need to manage its obligations under the note, including interest payments and potential conversion.
• The company will need to ensure it maintains its stock listing and complies with SEC reporting requirements to avoid default.

Key Dates

Keywords

convertible note, financing, common stock, securities purchase agreement, working capital, conversion price, default, prepayment, dilution, OTC Markets